Olmutinib 600 mg QD in Patients With T790M-positive NSCLC After Treatment With an EGFR-TKI
Clinical trial NCT04510415 · TERMINATED
Trial details
- NCT number
- NCT04510415
- Sponsor
- Hanmi Pharmaceutical Company Limited
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-03-29
- Primary completion
- 2018-12-11
- Enrollment
- 2
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.